Abstract
Background and Aim Type 2 diabetes mellitus (T2DM) is a major risk factor for heart failure, ischemic heart disease, and cardiac arrhythmias. Our goal is to examine the association of T2DM with ECG and cardiac imaging biomarkers, providing a window into the adverse effects of T2DM on cardiac health.
Methods Using data from the UK Biobank, we investigated ECG and cardiac magnetic resonance imaging biomarkers in a cohort of 1781 participants with T2DM and no diagnosed cardiovascular disease at time of assessment. We performed a pair-matched cross-sectional study to examine the association between type 2 diabetes and multi-modal cardiac biomarkers. We built multivariate multiple linear regression models sequentially adjusted for socio-demographic, lifestyle, and clinical covariates.
Results T2DM was associated with a higher resting heart rate (66 vs 61 beats per minute, p<0.001), longer QTc interval (424 vs 420 ms, p<0.001), reduced T-wave amplitude (0.33 vs 0.37 mV, p<0.001), lower stroke volume (72 vs 78 ml, p<0.001) and thicker left ventricular wall (6.1 vs 5.9 mm, p<0.001). These trends were consistent in subgroups of different sex, age and body mass index. Fewer significant differences were noted in non-white participants. QRS duration and Sokolow-Lyon index were associated with the development of cardiovascular disease in groups with and without T2DM, respectively. A higher left ventricular mass and wall thickness were associated with cardiovascular outcomes in both groups.
Conclusion T2DM was associated with adverse changes in ECG and cardiac imaging biomarkers, possibly reflecting subclinical cardiac repolarisation abnormalities, autonomic dysfunction, hypertrophy and impaired mechanical function.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
- Engineering and Physical Sciences Research Council Centre for Doctoral Training in Health Data Science scholarship (EP/S02428X/1) (A.B.) - Wellcome Trust Fellowship in Basic Biomedical Sciences (214290/Z/18/Z) (B.R.) - NIHR Oxford Biomedical Research Centre and the British Heart Foundation Oxford Centre for Research Excellence (RE/18/3/34214) (A.L.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The United Kingdom's National Health Service Research Ethics Service gave ethical approval for all work conducted using UK Biobank data (11/NW/0382).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data underlying this article were provided by the UK Biobank upon application. Access to UK Biobank data for research purposes can be obtained upon application (https://www.ukbiobank.ac.uk/).
